Literature DB >> 11703346

Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers.

R D Keenan1, J Ainsworth, N Khan, R Bruton, M Cobbold, M Assenmacher, D W Milligan, P A Moss.   

Abstract

Cytomegalovirus (CMV) reactivation and disease remains an important clinical problem for patients after allogeneic stem cell transplantation. Impaired cellular immune control of viral replication is responsible for viral reactivation, and transfer of CMV-specific T cells from transplant donors can be effective in providing protection. Recent reports have indicated that the frequency of CMV-specific CD8(+) T cells in the peripheral blood of healthy donors is surprisingly high. Here we demonstrate that by using a combination of human leucocyte antigen (HLA) Class I-peptide tetramers and magnetic selection it is possible to select CMV-specific T cells from CMV antibody-positive individuals to high purity. Reliable purification of CMV-specific T cells up to 99.8% of CD8(+) cells was possible within hours, even when starting with a precursor frequency of < 0.1% of peripheral blood CD8(+) T cells. CMV-specific T cells remained functional after the selection process. This novel form of antigen-specific T-cell selection should facilitate the selection of T cells for cellular immunotherapy to treat or prevent CMV disease after transplantation. In addition, this technique could potentially be applied to many antigens including against other infective agents and tumour-specific antigens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703346     DOI: 10.1046/j.1365-2141.2001.03106.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Shortening the immunodeficient period after hematopoietic stem cell transplantation.

Authors:  Isabelle André-Schmutz; Emmanuelle Six; Delphine Bonhomme; Julien Rouiller; Liliane Dal Cortivo; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 2.  Immunotherapy for transplantation-associated viral infections.

Authors:  Claire Roddie; Karl S Peggs
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

3.  Procedure for preparing peptide-major histocompatibility complex tetramers for direct quantification of antigen-specific cytotoxic T lymphocytes.

Authors:  Xian-Hui He; Li-Hui Xu; Yi Liu
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

4.  T cell control of primary and latent cytomegalovirus infections in healthy subjects.

Authors:  Anna K Lidehall; Fredrik Sund; Tobias Lundberg; Britt-Marie Eriksson; Thomas H Tötterman; Olle Korsgren
Journal:  J Clin Immunol       Date:  2005-09       Impact factor: 8.317

Review 5.  The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude.

Authors:  Marc K Jenkins; James J Moon
Journal:  J Immunol       Date:  2012-05-01       Impact factor: 5.422

Review 6.  Cytomegalovirus infection/disease after hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Jun Kato
Journal:  Int J Hematol       Date:  2010-04-23       Impact factor: 2.490

Review 7.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

Review 8.  Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.

Authors:  Ellen Meijer; Greet J Boland; Leo F Verdonck
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

9.  Tracking epitope-specific T cells.

Authors:  James J Moon; H Hamlet Chu; Jason Hataye; Antonio J Pagán; Marion Pepper; James B McLachlan; Traci Zell; Marc K Jenkins
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

10.  One-pot, mix-and-read peptide-MHC tetramers.

Authors:  Christian Leisner; Nina Loeth; Kasper Lamberth; Sune Justesen; Christina Sylvester-Hvid; Esben G Schmidt; Mogens Claesson; Soren Buus; Anette Stryhn
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.